FR23C1002I2 - 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse - Google Patents

2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse

Info

Publication number
FR23C1002I2
FR23C1002I2 FR23C1002C FR23C1002C FR23C1002I2 FR 23C1002 I2 FR23C1002 I2 FR 23C1002I2 FR 23C1002 C FR23C1002 C FR 23C1002C FR 23C1002 C FR23C1002 C FR 23C1002C FR 23C1002 I2 FR23C1002 I2 FR 23C1002I2
Authority
FR
France
Prior art keywords
migraine
benzamide
piperidin
trifluoro
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1002C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colucid Pharmaceuticals Inc
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42826711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1002(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of FR23C1002I1 publication Critical patent/FR23C1002I1/fr
Application granted granted Critical
Publication of FR23C1002I2 publication Critical patent/FR23C1002I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR23C1002C 2009-04-02 2023-01-11 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse Active FR23C1002I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16609709P 2009-04-02 2009-04-02
PCT/US2010/029810 WO2010115125A2 (en) 2009-04-02 2010-04-02 Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide

Publications (2)

Publication Number Publication Date
FR23C1002I1 FR23C1002I1 (fr) 2023-03-10
FR23C1002I2 true FR23C1002I2 (fr) 2023-11-24

Family

ID=42826711

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1002C Active FR23C1002I2 (fr) 2009-04-02 2023-01-11 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse

Country Status (25)

Country Link
US (2) US20100256187A1 (ja)
EP (1) EP2413933B2 (ja)
JP (8) JP5727457B2 (ja)
KR (1) KR101697801B1 (ja)
CN (2) CN102753171A (ja)
AU (1) AU2010232497B2 (ja)
CA (1) CA2757019C (ja)
CY (2) CY1119785T1 (ja)
DK (1) DK2413933T4 (ja)
ES (1) ES2655881T5 (ja)
FI (1) FIC20230001I1 (ja)
FR (1) FR23C1002I2 (ja)
HK (1) HK1243923A1 (ja)
HR (1) HRP20171742T4 (ja)
HU (2) HUE037261T2 (ja)
IL (1) IL215483A (ja)
LT (2) LT2413933T (ja)
MX (1) MX2011010359A (ja)
NL (1) NL301214I2 (ja)
NO (2) NO2413933T3 (ja)
NZ (1) NZ596161A (ja)
PL (1) PL2413933T5 (ja)
PT (1) PT2413933T (ja)
SI (1) SI2413933T2 (ja)
WO (1) WO2010115125A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US9943401B2 (en) 2008-04-04 2018-04-17 Eugene de Juan, Jr. Therapeutic device for pain management and vision
NZ596161A (en) * 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
EP3014345A2 (en) 2013-06-26 2016-05-04 Nexisvision, Inc. Contact lenses for refractive correction
TN2019000174A1 (en) * 2016-12-06 2020-10-05 Colucid Pharmaceuticals Inc Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
TWI826514B (zh) * 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
TR199700993T1 (xx) 1995-03-20 1998-03-21 Eli Lilly And Company 5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6777428B1 (en) * 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
EP1299334B1 (en) * 2000-07-13 2008-01-16 MERCK PATENT GmbH Chiral compounds i
US6650463B2 (en) * 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
US20050080112A1 (en) * 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
AU2003295782A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
AU2004232799A1 (en) * 2003-04-18 2004-11-04 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
EP1651595A2 (en) * 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
KR20060067738A (ko) * 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
KR100976063B1 (ko) * 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
NZ596161A (en) † 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8697876B2 (en) * 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists

Also Published As

Publication number Publication date
CN102753171A (zh) 2012-10-24
JP7110446B2 (ja) 2022-08-01
PL2413933T3 (pl) 2018-04-30
JP2023175694A (ja) 2023-12-12
FIC20230001I1 (fi) 2023-01-10
US20210401822A1 (en) 2021-12-30
EP2413933B2 (en) 2021-06-09
DK2413933T4 (da) 2021-08-23
CY2023001I1 (el) 2023-03-24
KR101697801B1 (ko) 2017-01-18
AU2010232497A1 (en) 2011-11-24
WO2010115125A3 (en) 2011-02-17
CA2757019C (en) 2018-05-15
ES2655881T3 (es) 2018-02-22
EP2413933A4 (en) 2012-09-19
CY1119785T1 (el) 2018-06-27
HK1243923A1 (zh) 2018-07-27
HUE037261T2 (hu) 2018-08-28
IL215483A (en) 2017-07-31
JP7566996B2 (ja) 2024-10-15
JP2016188241A (ja) 2016-11-04
IL215483A0 (en) 2011-12-29
SI2413933T2 (sl) 2021-09-30
US20100256187A1 (en) 2010-10-07
JP2022163049A (ja) 2022-10-25
JP2018087247A (ja) 2018-06-07
CA2757019A1 (en) 2010-10-07
LT2413933T (lt) 2018-02-26
JP2015013903A (ja) 2015-01-22
ES2655881T5 (es) 2021-11-25
NO2413933T3 (ja) 2018-03-31
EP2413933B1 (en) 2017-11-01
CN107412230A (zh) 2017-12-01
NL301214I2 (nl) 2023-04-19
DK2413933T3 (da) 2018-01-29
EP2413933A2 (en) 2012-02-08
PL2413933T5 (pl) 2021-10-18
JP2012522805A (ja) 2012-09-27
HRP20171742T4 (hr) 2021-08-06
SI2413933T1 (en) 2018-04-30
WO2010115125A2 (en) 2010-10-07
JP7335397B2 (ja) 2023-08-29
NL301214I1 (ja) 2023-01-25
HUS2300004I1 (hu) 2023-02-28
FR23C1002I1 (fr) 2023-03-10
MX2011010359A (es) 2012-02-23
HRP20171742T1 (hr) 2018-02-09
KR20110136893A (ko) 2011-12-21
JP2021152008A (ja) 2021-09-30
JP2019189617A (ja) 2019-10-31
PT2413933T (pt) 2017-12-12
LTPA2023502I1 (ja) 2023-01-25
NO2023002I1 (no) 2023-01-05
JP5727457B2 (ja) 2015-06-03
JP6887462B2 (ja) 2021-06-16
NZ596161A (en) 2013-11-29
CY2023001I2 (el) 2023-06-09
AU2010232497B2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
FR23C1002I2 (fr) 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse
ATE541845T1 (de) 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
FR2928832B1 (fr) Orthese de poignet, destinee au traitement du syndrome du canal carpien
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
FR3004920B1 (fr) Dispositif d&#39;osteotomie, en particulier pour la realisation du scarf extreme dans le traitement de l&#39;hallux valgus severe.
EA201500362A1 (ru) Ингибиторы rho-киназы
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
WO2015001504A3 (en) Antibody formulations and methods
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0816116A2 (pt) Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
FR2932478B1 (fr) Composes utiles pour le traitement des cancers.
FR2948016B1 (fr) Orthese pour le traitement de la rhizarthrose
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201170832A1 (ru) Пуриновые соединения
MA46490A1 (fr) Dérivés de nucléosides 4&#39;- fluoro-2&#39; - méthyle substitués
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
EA201171063A1 (ru) Фармацевтические составы олмесартана
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
BRPI0923567A2 (pt) agentes antibactericidas novos para o tratamento de infecções gram positivas
DOP2010000373A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
ITMI20110598A1 (it) Procedimento e apparecchio di comando per l&#39;adattamento del rumore di marcia
MA45552A (fr) Compositions destinées au traitement de l&#39;amylose